Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Inclusion Criteria: * Has confirmed biliary tract cancer * Ability to understand and willingness to sign a written informed consent document. * Age ≥18 years * Have biopsiable disease * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Patient must have adequate organ function defined by the study-specified laboratory tests. * Must use acceptable form of birth control while on study. Exclusion Criteria: * Has active autoimmune disease that requires systemic treatment. * Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years. * Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.). * Has known central nervous system (CNS) metastases and/or carcinomatous meningitis. * Has evidence of interstitial lung disease or active, non-infectious pneumonitis. * Has evidence of an uncontrolled, active infection requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy ≤ 7 days prior to administration of study medication. * Has received a blood transfusion within 72 hours prior to first dose of study drug administration * Unwilling or unable to follow the study schedule for any reason. * Major surgery within 4 weeks prior to initiation of study treatment. * Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant muscle disorders or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breastfeeding women. * Have known history of infection with HIV, hepatitis B, or hepatitis C. * Received any prophylactic vaccine within 30 days of first dose of study drug treatment. * Has a history of allergy to study treatments or any of its components of the study.